1. Vimentin 3 Expression in Prostate Cancer Cells
- Author
-
Barbara Köditz, Andreas Stog, Heike Göbel, Axel Heidenreich, Melanie von Brandenstein, Isabell Heidegger, and Jochen W.U. Fries
- Subjects
Male ,Cancer Research ,Cell ,Gene Expression ,Vimentin ,Prostate cancer ,DU145 ,Cell Movement ,Cell Line, Tumor ,LNCaP ,Biomarkers, Tumor ,medicine ,Humans ,Receptor ,Cells, Cultured ,Endothelin-1 ,biology ,Chemistry ,Prostatic Neoplasms ,General Medicine ,medicine.disease ,Endothelin 1 ,medicine.anatomical_structure ,Oncology ,biology.protein ,Cancer research ,Endothelin receptor - Abstract
Background/aim Vimentin3 (Vim3) was recently described as a tumour marker for the direct discrimination between benign and malignant kidney tumours. Here, we examined its expression in prostate cancer (PCa) cell lines and the regulation of its expression by endothelin receptors. Materials and methods Prostate cancer cell lines (PC3, DU145, LNCap) were incubated with endothelin 1 (ET-1), BQ123 [endothelin A receptor (ETAR) antagonist], BQ788 [endothelin B receptor (ETBR) antagonist], BQ123+ET-1, BQ788+ET-1 for 24 h and a scratch assay was performed. Cell extracts were analysed by western blotting and qRT-PCR. Results ET-1 induced Vim3 overexpression. Blocking the ETBR in the different prostate cancer cell lines yielded a higher migration rate, whereby Vim3 expression was significantly increased. Conclusion Vim3 concentration increases in cell lines without a functional ETBR and may be used as a marker for PCas where ETBR is frequently methylated.
- Published
- 2021
- Full Text
- View/download PDF